Canada Pension Plan Investment Board Acquires New Position in United Therapeutics Corporation $UTHR

Key Points

• Canada Pension Plan Investment Board established a new United Therapeutics position in the second quarter, purchasing 6,200 shares valued at approximately $3.36 million. Institutional investors collectively own 94.08% of UTHR.
• United Therapeutics insiders have recently sold substantial amounts of stock: the CEO and CFO sold a combined 19,500 shares, while insiders sold 404,575 shares worth about $216.7 million over the past 90 days.
• Analysts maintain a generally positive outlook, with an average rating of “Moderate Buy” and a $646 price target. The company exceeded quarterly EPS expectations, reporting $7.27 per share, although revenue fell 1.9% year over year to $783.3 million.

Canada Pension Plan Investment Board bought a new position in United Therapeutics Corporation (NASDAQ:UTHR - Free Report) in the 2nd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor bought 6,200 shares of the biotechnology company's stock, valued at approximately $3,359,000.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in UTHR. Arjuna Capital boosted its position in shares of United Therapeutics by 2.8% in the first quarter. Arjuna Capital now owns 662 shares of the biotechnology company's stock worth $393,000 after purchasing an additional 18 shares during the period. Sage Rhino Capital LLC raised its position in shares of United Therapeutics by 5.1% during the 1st quarter. Sage Rhino Capital LLC now owns 474 shares of the biotechnology company's stock valued at $281,000 after purchasing an additional 23 shares during the period. Bryn Mawr Trust Advisors LLC lifted its stake in shares of United Therapeutics by 5.4% during the 1st quarter. Bryn Mawr Trust Advisors LLC now owns 465 shares of the biotechnology company's stock valued at $276,000 after buying an additional 24 shares in the last quarter. Meeder Advisory Services Inc. lifted its stake in shares of United Therapeutics by 4.1% during the 1st quarter. Meeder Advisory Services Inc. now owns 661 shares of the biotechnology company's stock valued at $392,000 after buying an additional 26 shares in the last quarter. Finally, Independent Advisor Alliance boosted its holdings in United Therapeutics by 3.3% in the 4th quarter. Independent Advisor Alliance now owns 833 shares of the biotechnology company's stock worth $406,000 after buying an additional 27 shares during the period. Institutional investors own 94.08% of the company's stock.

Insider Transactions at United Therapeutics

In related news, CEO Martine A. Rothblatt sold 9,500 shares of United Therapeutics stock in a transaction dated Wednesday, June 3rd. The stock was sold at an average price of $547.61, for a total value of $5,202,295.00. Following the completion of the transaction, the chief executive officer owned 40,513 shares in the company, valued at approximately $22,185,323.93. This trade represents a 19.00% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CFO James Edgemond sold 10,000 shares of United Therapeutics stock in a transaction dated Thursday, June 4th. The stock was sold at an average price of $546.28, for a total value of $5,462,800.00. Following the completion of the transaction, the chief financial officer owned 18,876 shares of the company's stock, valued at approximately $10,311,581.28. This represents a 34.63% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders sold 404,575 shares of company stock valued at $216,652,640. 8.60% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

UTHR has been the subject of a number of analyst reports. TD Cowen reiterated a "buy" rating on shares of United Therapeutics in a research note on Thursday, May 21st. Weiss Ratings downgraded United Therapeutics from a "buy (b)" rating to a "buy (b-)" rating in a research report on Thursday. Morgan Stanley set a $515.00 price objective on United Therapeutics in a research note on Thursday, August 6th. Bank of America cut their target price on United Therapeutics from $620.00 to $613.00 and set a "neutral" rating for the company in a research report on Friday, July 10th. Finally, Royal Bank Of Canada lowered their price target on United Therapeutics from $704.00 to $677.00 and set an "outperform" rating on the stock in a report on Thursday, August 6th. Eleven analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company's stock. According to data from MarketBeat, United Therapeutics presently has an average rating of "Moderate Buy" and an average target price of $646.00.

United Therapeutics Stock Performance

NASDAQ UTHR opened at $515.46 on Monday. The stock has a 50 day moving average price of $530.46 and a 200-day moving average price of $539.16. United Therapeutics Corporation has a one year low of $303.08 and a one year high of $609.35. The company has a market capitalization of $22.11 billion, a P/E ratio of 18.44, a P/E/G ratio of 1.75 and a beta of 0.59.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last issued its quarterly earnings data on Wednesday, August 5th. The biotechnology company reported $7.27 EPS for the quarter, topping analysts' consensus estimates of $6.86 by $0.41. United Therapeutics had a net margin of 41.56% and a return on equity of 20.18%. The business had revenue of $783.30 million during the quarter, compared to analysts' expectations of $804.65 million. During the same period last year, the company posted $6.41 EPS. The business's revenue was down 1.9% on a year-over-year basis. As a group, equities analysts predict that United Therapeutics Corporation will post 26.33 EPS for the current fiscal year.

About United Therapeutics

United Therapeutics Corporation NASDAQ: UTHR is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company's primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source